



Type 1 diabetes is a chronic autoimmune disease that develops when the immune system mistakenly attacks its own beta cells in the pancreas.

Beta cells normally produce insulin, which allows the body to use energy from food and helps control blood sugar levels. Without insulin, the body cannot function properly.

The DESIGNATE study will test whether an investigational drug call *siplizumab*, will reduce or block the T-cells that attack the beta cells in your pancreas.

To learn more about the **DESIGNATE** trial, visit **designate-study.org**.





designate-study.org





DESIGNATE is being conducted by the Immune Tolerance Network (ITN) and sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) (NIH funded)